Acta Scientific Cancer Biology (ASCB) (ISSN: 2582-4473)

Short Communication Volume 7 Issue 2

CAR-T Therapy for Solid Cancer: Challenges and Solutions

Deepak Rohila*

Department of Pathology, Uniformed Services University of the Health Sciences and Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, USA

*Corresponding Author: Deepak Rohila, Department of Pathology, Uniformed Services University of the Health Sciences and Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, USA.

Received: February 27, 2023; Published: March 27, 2023

Abstract

CAR-T therapy, or chimeric antigen receptor T-cell therapy, has shown remarkable success in treating certain blood cancers, such as leukemia and lymphoma. However, the use of CAR-T therapy for solid tumors has been more challenging. Solid tumors are complex and heterogeneous, making it difficult to identify specific antigens that can be targeted by CAR-T cells. In addition, solid tumors often have a hostile microenvironment that can inhibit CAR-T cell function and survival.

References

  1. Hegde M., et al. “Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape”. Journal of Clinical Investigation8 (2016): 3036-3052.
  2. Newick K., et al. “CAR T Cell Therapy for Solid Tumors”. Annual Review of Medicine 68 (2017): 139-152.
  3. Drent E., et al. “Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma”. Haematologica5 (2016): 616-625.
  4. Liu X., et al. “A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors”. Cancer Research6 (2016): 1578-1590.
  5. Zhang E., et al. “Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors”. Molecular Cancer 17 (2018): 7.

Citation

Citation: Deepak Rohila. “CAR-T Therapy for Solid Cancer: Challenges and Solutions" Acta Scientific Cancer Biology 7.2 (2023): 03-04.

Copyright

Copyright: © 2023 Deepak Rohila. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate35%
Acceptance to publication20-30 days
Impact Factor1.183

Indexed In




News and Events


Contact US